NKGN

0.00300.00%
CB

Craig Blackstone

Member of Scientific Advisory Board

Dr. Craig Blackstone, M.D., Ph.D., is Member of Scientific Advisory Board at NKGen Biotech, Inc. since March 2023. He is Chair of Scientific Advisory Board & Director of Asha Therapeutics, LLC from 2022. He is Chief of the Movement Disorders Division at the Massachusetts General Hospital and Professor of Neurology at Harvard Medical School. After neurology residency in the Harvard-Longwood Neurology Program, Dr. Blackstone pursued clinical fellowship training in movement disorders at Massachusetts General Hospital and postdoctoral research training in neurobiology with Dr. Morgan Sheng at Harvard Medical School and the Howard Hughes Medical Institute. Previously he was Senior Investigator and Cell Biology Section Chief within the National Institute of Neurological Disorders (NINDS) Neurogenetics Branch of the National Institutes of Health (NIH). Dr. Blackstone is a distinguished investigator focusing his research on investigating the cellular pathogenesis of neurogenetic disorders. In 2001, Dr. Blackstone joined the NINDS, rising to Senior Investigator and Cell Biology Section Chief. His group investigated the cellular and molecular mechanisms underlying hereditary movement disorders. He is an elected Member of the American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP) as well as an elected Fellow and former Vice President of the American Neurological Association (ANA). He currently serves on the editorial boards of the Journal of Clinical Investigation and Journal of Neuromuscular Diseases. He received the NIH Director's Ruth L. Kirschstein Mentoring Award in 2012 and the NINDS Director’s Diversity Achievement Award in 2018. He received B.S./M.S. degrees from the University of Chicago and M.D./Ph.D. degrees in Medicine and Neuroscience from The Johns Hopkins University School of Medicine.

Positions